Daphne Koller, insitro CEO (Stefan Wermuth/Bloomberg via Getty Images)
October 9, 2024 07:00 AM EDTUpdated 10:23 AM
Deals
R&D
AI

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Ryan Cross

Senior Science Correspondent

If all goes ac­cord­ing to plan, in­sitro could fi­nal­ly start test­ing its first drug in clin­i­cal tri­als in 2026, eight years af­ter Daphne Koller found­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times